The Neurodiagnostics Report 2012: Brain Imaging, Biomarkers and NeuroInformatics
Published April 2012
Fully updated third annual industry insider report detailing markets and emerging diagnostics in neurology and psychiatry.
Nearly 2 billion people worldwide and 100 million people in the US are affected by a brain or nervous system disorder including addiction, Alzheimer’s, depression, anxiety, schizophrenia, attention disorders, epilepsy, Parkinson’s disease, sensory disorders, and sleep disorders. Diagnosis of these disorders is rapidly changing as new tools are developed for more objective and personalized assessment and treatment.
In addition to the massive unmet markets, long term growth in neurodiagnostics is being driven by 1) technology advances and equipment upgrades in neuroimaging, 2) new biomarkers and imaging protocols for early diagnosis and disease monitoring, and 3) increased use of imaging and informatics in drug and device development.
Table of Contents
Over 150 Companies Included
|
NeuroInsights has identified three primary markets in neurodiagnostics which are discussed in
detail in this report:
-
Neuroimaging: Medical equipment and reagents for research, diagnostics and patient monitoring, including MRI, CT, PET, SPECT, EEG and MEG.
-
In vitro diagnostics: Genetic testing, biomarker assays and chemical profiling of human samples, including urine, blood, cerebral spinal fluid and tissue.
-
Neuroinformatics: Multidimensional databases and software systems that store and analyze data from the genetic to the behavioral level.
|
|
|
